[In silico, in vitro, in omic experimental models and drug safety evaluation].
Over the last few decades, toxicology has benefited from scientific, technical, and bioinformatic developments relating to patient safety assessment during clinical and drug marketing studies. Based on this knowledge, new in silico, in vitro, and "omic" experimental models are emerging. Although these models cannot currently replace classic safety evaluations performed on laboratory animals, they allow compounds with unacceptable toxicity to be rejected in the early stages of drug development, thereby reducing the number of laboratory animals needed. In addition, because these models are particularly adapted to mechanistic studies, they can help to improve the relevance of the data obtained, thus enabling better prevention and screening of the adverse effects that may occur in humans. Much progress remains to be done, especially in the field of validation. Nevertheless, current efforts by industrial, academic laboratories, and regulatory agencies should, in coming years, significantly improve preclinical drug safety evaluation thanks to the integration of these new methods into the drug research and development process.
Claude
Nancy
N
Institut de Recherches Internationales Servier, 6, place des Pléiades, 92415 Courbevoie, France. nancy.claude@fr.netgrs.com
Goldfain-Blanc
Françoise
F
Guillouzo
André
A
D015415:Biomarkers; D002454:Cell Differentiation / Q000502:physiology; D016678:Genome / Q000187:drug effects; D008660:Metabolism; D004364:Pharmaceutical Preparations / Q000592:standards*; D020543:Proteome; D021281:Quantitative Structure-Activity Relationship; D012449:Safety; D014116:Toxicology / Q000592:standards*; D014158:Transcription, Genetic
D015415:Biomarkers; D004364:Pharmaceutical Preparations; D020543:Proteome